Dr. Buelow has worked in biotechnology for over twenty years and has extensive pharmaceutical experience. Dr. Buelow is a founder of OMT (2007), a fully human monoclonal antibody platform based on transgenic rats, and THP, Inc. (2003), a biotechnology company that engineered rabbits to produce human antibodies and was acquired by Roche in March 2007. Between 1993 and 2003, Dr. Buelow was senior vice president of Research and Development at SangStat Medical Corporation, where he developed RDP58, an anti-inflammatory compound that demonstrated efficacy in a placebo-controlled, blinded Phase II study in ulcerative colitis patients. Dr. Buelow has published more than 100 manuscripts and is an inventor on more than 25 patents.
Stephen Dance joined Teneobio in February 2016 and brings over thirty years’ experience in finance and accounting. Prior to joining Teneobio, Mr. Dance was Chief Financial Officer at Apple Tree Partners, a life sciences venture capital firm, from 2011 to 2013. He held the same position at NICHQ Inc., a company focused on improving health outcomes for children, from 2009 to 2011. Prior to that, he served as Senior Vice President, Finance and Chief Financial Officer at ViaCell, Inc., a biotechnology company, from 2004 to 2007, including taking ViaCell public in 2005. He was Senior Vice President, Finance and Chief Financial Officer at SangStat Medical Corporation, a publicly-held biotechnology company, from 1999 to 2003 when SangStat was acquired by Genzyme (now Sanofi). Mr. Dance also spent fifteen years with Syntex Corporation, a pharmaceuticals company (now part of the Roche group), in a variety of increasingly responsible finance positions including controller of all US pharmaceutical operations. Mr. Dance started his career with Deloitte & Touche in the London and San Francisco offices. He is a CPA and holds a B.A. degree in French and Spanish from the University of Leeds in England.
Dr. Ben Buelow joined Teneobio as Chief Medical Officer in 2016. He also serves as adjunct/volunteer faculty in the UCSF department of pathology. Ben completed his residency and surgical pathology fellowship as chief resident at UCSF in 2016. He received an MD with honors and a PhD in Immunology from the University of Washington in 2011. Ben is author of 14 peer reviewed publications and has presented at numerous national and international scientific meetings.
Dr. van Schooten has over 20 years of biotechnology management experience, including research and development supervision, manufacturing and regulatory operations. Dr. van Schooten co-founded THP, Inc. with Dr. Buelow in 2000 and served as its Chief Executive Officer from 2002 until its sale to Roche Pharmaceuticals in March 2007. From 1993 to1999, he led the development of therapeutics for the treatment of prostate cancer and multiple myeloma at Dendreon. Dr. van Schooten also directed the quality and clinical research programs, leading to the approval of a device and Phase III studies in cancers. Dr. van Schooten studied Immunology at the University of Leiden and the Royal Tropical Institute in Amsterdam.
Dr. Vafa joined TeneoBio as Chief Business Officer in February 2016. He has more than 15 years of global business and scientific experience in biotechnology and pharmaceutical drug discovery, asset evaluation, transactions and licensing. Prior to joining TeneoBio, Dr. Vafa was the Director of Strategy and Scientific Partnerships at Janssen Pharmaceutical Companies of Johnson and Johnson and the Biotechnology and Oncology Lead at the London Innovation Center of J&J. Dr. Vafa earned his doctorate at Georgetown University, his MBA from the Villanova University School of Business, and his B.S. from the University of California at Irvine. He completed his post-doctoral fellowships at The Scripps Research Institute (TSRI) and the Salk Institute for Biological Studies in La Jolla, California.
Dr. Iyer has over 20 years of experience in the biotech industry that spans drug discovery, translational research, regulatory interactions and clinical development. Prior to joining Teneobio in April 2017, Dr. Iyer was at Abbvie as Global Project Leader in Oncology Clinical Development where she led programs in early development. Prior to Abbvie, Dr. Iyer was at Genentech for 11 years during which she led preclinical and clinical development teams in immunology and oncology, resulting in key development milestones and numerous IND filings for several programs. She began her R&D career at Sangstat Medical Corp with over 9 years in discovery and early development research. She earned her Ph.D. from University of California at Davis, is a co-author on over 40 publications, has presented at numerous national and international forums and is a co-inventor on 5 patents.
Dr. Trinklein is currently Vice President of Discovery at Teneobio. His group employs a new sequence-based approach for antibody discovery that leverages next-gen sequence and high-throughput recombinant expression to screen large numbers of diverse sequence-defined antibodies. Prior to Teneobio, Dr. Trinklein was co-founder and CEO of SwitchGear Genomics, a venture-backed company that was acquired in 2013. SwitchGear developed and commercialized a unique cell-based platform for small molecule pathway screening. Dr. Trinklein served as the Technical Director of the Stanford ENCODE project and received his Ph.D from Stanford University. Dr. Trinklein has published over 20 peer-reviewed papers and is an inventor on over 15 patents.
Shelley Force Aldred serves as VP for Preclinical Development at TeneoBio. Her group has developed a high-throughput workflow for evaluating thousands of lead antibodies in challenging cell-based models. Dr. Force Aldred was formerly director of worldwide R&D for Active Motif, which she joined in 2013 when Active Motif acquired SwitchGear Genomics. In 2006, she co-founded SwitchGear Genomics, a venture-backed functional genomics tools company, and she served as its President and Board Member. Prior to founding SwitchGear Genomics, Dr. Force Aldred was a graduate student then senior scientist on Stanford’s ENCODE Project team. She is an inventor on multiple issued patents and an author on many peer-reviewed scientific publications.
Dr. Schellenberger assumed the role of Vice President, Protein Science in November 2015 and brings extensive expertise in protein biochemistry, lead characterization and process development to Teneobio. Previously, she held various leadership positions within the R&D departments of Dupont Pioneer and prior to that at Scios – a Johnson & Johnson company. Her work in protein discovery, engineering and analytics has resulted in numerous publications and issued patents. Dr. Schellenberger received her Ph.D. degree in Biochemistry from the University of Leipzig in Germany. She completed her graduate studies in the Institute of Protein Research, Pushchino, Russia. In 1991 she relocated to California and joined UCSF as a postdoctoral fellow to study protein engineering and enzymology.